Renal Cancer Treatment: A Review of the Literature
Luca Gattinoni(National Cancer Institute), Emilio Bajetta(Fondazione Lanza), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Biagio Agostara, Leonardo Ferrari, P. Nova(Sorbonne Université), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Agata Laudani(University of Palermo), Massimiliano Alù(University of Palermo)
Cited by 17
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
|Journal of Clinical Investigation|2005|949